Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer

European Journal of Cancer

Volumn 47, Issue 12, 2011, Pages 1779-1788

  Yasojima, Hiroyuki ^a   Shimomura, Atsushi ^a   Naoi, Yasuto ^a   Kishi, Kazuki ^b   Baba, Yousuke ^b   Shimazu, Kenzo ^a   Nakayama, Takahiro ^a   Kim, Seung Jin ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SYSMEX CORPORATION   (Japan)

Author keywords

Breast cancer; C myc amplification; Chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; MYC PROTEIN; PACLITAXEL; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CELL LOSS; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ODDS RATIO; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, MAMMARY;

EID: 80051546563     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.06.017     Document Type: Article

References (29)

1. N.E. Hynes, and T. Stoelzle Key signalling nodes in mammary gland development and cancer: Myc Breast Cancer Res 11 5 2009 210
2. C.V. Dang, K.A. O'Donnell, and K.I. Zeller The c-Myc target gene network Semin Cancer Biol 16 4 2006 253 264 (Pubitemid 44311039)
3. Y. Chen, and O.I. Olopade MYC in breast tumor progression Expert Rev Anticancer Ther 8 10 2008 1689 1698
4. E.C. Robanus-Maandag, C.A. Bosch, and P.M. Kristel Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas J Pathol 201 1 2003 75 82 (Pubitemid 37121205)
5. T.A. Rose-Hellekant, and E.P. Sandgren Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice Oncogene 19 8 2000 1092 1096 (Pubitemid 30153795)
6. S.L. Deming, S.J. Nass, R.B. Dickson, and B.J. Trock C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance Br J Cancer 83 12 2000 1688 1695 (Pubitemid 32001715)
7. S. Aulmann, N. Adler, and J. Rom C-myc amplifications in primary breast carcinomas and their local recurrences J Clin Pathol 59 4 2006 424 428
8. K. Al-Kuraya, P. Schraml, and J. Torhorst Prognostic relevance of gene amplifications and coamplifications in breast cancer Cancer Res 64 23 2004 8534 8540 (Pubitemid 39552065)
9. B. Hoffman, and D.A. Liebermann Apoptotic signaling by c-MYC Oncogene 27 50 2008 6462 6472
10. A. Vincent-Salomon, A. Rousseau, and M. Jouve Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy Eur J Cancer 40 10 2004 1502 1508 (Pubitemid 38757737)
11. M.G. Bottone, C. Soldani, and G. Tognon Multiple effects of paclitaxel are modulated by a high c-myc amplification level Exp Cell Res 290 1 2003 49 59 (Pubitemid 37153250)
12. E. Olah, B. Csokay, and N. Prajda Molecular mechanisms in the antiproliferative action of taxol and tiazofurin Anticancer Res 16 5A 1996 2469 2477 (Pubitemid 26388203)
13. F.A. Fornari Jr. , W.D. Jarvis, and S. Grant Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin Cell Growth Differ 5 7 1994 723 733 (Pubitemid 24245303)
14. F.A. Fornari Jr. , D.W. Jarvis, and S. Grant Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin Biochem Pharmacol 51 7 1996 931 940 (Pubitemid 26109490)
15. S.M. Rodriguez-Pinilla, R.L. Jones, and M.B. Lambros MYC amplification in breast cancer: a chromogenic in situ hybridisation study J Clin Pathol 60 9 2007 1017 1023 (Pubitemid 47441935)
16. C.M. Schlotter, U. Vogt, U. Bosse, B. Mersch, and K. Wassmann C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer Breast Cancer Res 5 2 2003 R30 R36
17. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 2001 10869 10874 (Pubitemid 32878711)
18. Y. Miyoshi, M. Kurosumi, and J. Kurebayashi Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers J Cancer Res Clin Oncol 134 5 2008 561 567 (Pubitemid 351422609)
19. Y. Takahashi, Y. Miyoshi, and K. Morimoto Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers J Cancer Res Clin Oncol 133 8 2007 501 509 (Pubitemid 46955677)
20. G. Armengol, S. Knuutila, and F. Lluis DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma Cancer Genet Cytogenet 116 2 2000 133 141
21. C.B. Moelans, R.A. de Weger, H.N. Monsuur, R. Vijzelaar, and P.J. van Diest Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes Mod Pathol 23 7 2010 1029 1039
22. L.A. Carey, C.M. Perou, and C.A. Livasy Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 21 2006 2492 2502 (Pubitemid 43854964)
23. M.C. Cheang, S.K. Chia, and D. Voduc Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 10 2009 736 750
24. M.C. Alles, M. Gardiner-Garden, and D.J. Nott Meta-analysis and gene set enrichment relative to ER status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup PLoS One 4 3 2009 e4710
25. L. Burkhardt, T.J. Grob, and I. Hermann Gene amplification in ductal carcinoma in situ of the breast Breast Cancer Res Treat 123 3 2010 757 765
26. S. Miura, M. Nakashima, and M. Ito Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade Cancer 112 10 2008 2143 2151 (Pubitemid 351628622)
27. J. Blancato, B. Singh, A. Liu, D.J. Liao, and R.B. Dickson Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses Br J Cancer 90 8 2004 1612 1619 (Pubitemid 38648247)
28. J.K. Rummukainen, T. Salminen, and J. Lundin Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array Mod Pathol 14 10 2001 1030 1035 (Pubitemid 32976792)
29. K. Park, K. Kwak, J. Kim, S. Lim, and S. Han C-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers Hum Pathol 36 6 2005 634 639 (Pubitemid 40922569)